What SEC filings does Ligand Pharmaceuticals Incorporated submit to the SEC?

Ligand Pharmaceuticals Incorporated (LGND) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about LGND?

A Form 4 for LGND discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from Ligand Pharmaceuticals Incorporated?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for LGND?

The 10-K is Ligand Pharmaceuticals Incorporated's annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all LGND SEC filings directly on EDGAR?

You can view all historical Ligand Pharmaceuticals Incorporated filings on the SEC EDGAR company page for LGND. Each filing card on this page links directly to the original SEC document.

How often does Ligand Pharmaceuticals Incorporated file with the SEC?

Ligand Pharmaceuticals Incorporated files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling LGND shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

LGND SEC Filing News — Ligand Pharmaceuticals Incorporated

Latest SEC filings for Ligand Pharmaceuticals Incorporated (LGND) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-10-06.

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, develops and licenses biopharmaceutical assets worldwide. It offers Pradefovir, Posaconazole, Voriconazole, CAPVAXIVE, NOXAFIL, MenFive, and ZELSUVMI for infectious disease; EVOMELA and KYPROLIS for multiple myeloma; FILSPARI for the treatment of immunoglobulin a nephropathy; PNEUMOSIL, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia in children; and QARZIBA to treat neuroblastoma. The company also pr…

Sector: Healthcare Industry: Biotechnology Market Cap: $6.0B CIK: 886163

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for LGND currently lean bearish. Of the 20 filing records displayed, 8 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

LGND Filing Activity Snapshot 2026-07-06 — 2026-10-06

Insider Transactions (Form 4)

0 buys vs 7 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$9.24M

Espinoza Octavio (Chief Financial Officer) · 2026-08-14

31,641 shares · Form 4

Form 144 Notices

Proposed insider sales filed — Form 144 is a notice of intent, not a confirmed transaction. Actual sales are confirmed via Form 4.

Insider Transactions 10 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 10 filings in this group are Form 4s for Ligand Pharmaceuticals Incorporated.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 10 insider filings shown, the breakdown is 7 open-market sale, 2 other reported transaction and 1 tax withholding. 7 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Open-market sale ×7: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.
Other reported transaction ×2: The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.
Tax withholding ×1: Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Form 4 Open-market sale Insider Selling 2026-10-06

LGND insider Reardon Andrew (CLO & Secretary) sold 5,000 shares (~$1.52M)

Reardon Andrew, listed as CLO & Secretary at LIGAND PHARMACEUTICALS INC, reported an open-market sale of 5,000 LGND shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	340	$52.27	$17.8K
`S`	Open-market sale	833	$302.51	$252.0K
`S`	Open-market sale	1,976	$303.54	$599.8K
`S`	Open-market sale	1,535	$304.52	$467.4K
`S`	Open-market sale	404	$306.18	$123.7K
`S`	Open-market sale	235	$307.19	$72.2K
`S`	Open-market sale	17	$307.74	$5.2K
`M`	Option exercise derivative · Employee Stock Option (right to buy)	340	—	—

Filing: Form 4 (Insider Transaction) Insider: Reardon Andrew (CLO & Secretary) Shares: 5,000 Est. Value: $1.52M

View on SEC EDGAR → Open Filing Document →

Form 4 Tax withholding Tax / Compensation Filing 2026-09-24

LGND insider Form 4 filed for equity award, exercise, or tax withholding

Zimmermann Martine (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were withheld by the company to settle tax due when equity vested. This is an automatic administrative step and not a decision to sell.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`F`	Tax withholding on vested shares	115	$298.50	$34.3K

Filing: Form 4 (Insider Transaction) Insider: Zimmermann Martine (Director) Shares: 115

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-14

LGND insider Zimmermann Martine (Director) sold 1,200 shares (~$342.0K)

Zimmermann Martine, listed as Director at LIGAND PHARMACEUTICALS INC, reported an open-market sale of 1,200 LGND shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	1,200	$285.00	$342.0K

Filing: Form 4 (Insider Transaction) Insider: Zimmermann Martine (Director) Shares: 1,200 Est. Value: $342.0K

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-08

LGND insider Reardon Andrew (CLO & Secretary) sold 5,000 shares (~$1.43M)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	300	$283.99	$85.2K
`S`	Open-market sale	1,800	$285.17	$513.3K
`S`	Open-market sale	2,115	$286.36	$605.6K
`S`	Open-market sale	385	$287.53	$110.7K
`S`	Open-market sale	400	$288.98	$115.6K

Filing: Form 4 (Insider Transaction) Insider: Reardon Andrew (CLO & Secretary) Shares: 5,000 Est. Value: $1.43M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-14

LGND insider Espinoza Octavio (Chief Financial Officer) sold 31,641 shares (~$9.24M)

Espinoza Octavio, listed as Chief Financial Officer at LIGAND PHARMACEUTICALS INC, reported an open-market sale of 31,641 LGND shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	16,179	$52.84	$854.9K
`M`	Option exercise	2,074	$70.04	$145.3K
`M`	Option exercise	2,869	$55.75	$159.9K
`M`	Option exercise	7,171	$57.22	$410.3K
`M`	Option exercise	3,348	$68.74	$230.1K
`S`	Open-market sale	31,641	$292.06	$9.24M
`M`	Option exercise derivative · Employee Stock Option (right to buy)	2,869	—	—
`M`	Option exercise derivative · Employee Stock Option (right to buy)	7,171	—	—
`M`	Option exercise derivative · Non-Qualified Stock Option (right to buy)	16,179	—	—
`M`	Option exercise derivative · Non-Qualified Stock Option (right to buy)	3,348	—	—
`M`	Option exercise derivative · Non-Qualified Stock Option (right to buy)	2,074	—	—

Filing: Form 4 (Insider Transaction) Insider: Espinoza Octavio (Chief Financial Officer) Shares: 31,641 Est. Value: $9.24M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-14

LGND insider Haas Jason (Director) sold 7,138 shares (~$2.09M)

Haas Jason, listed as Director at LIGAND PHARMACEUTICALS INC, reported an open-market sale of 7,138 LGND shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	6,138	$51.56	$316.5K
`S`	Open-market sale	7,138	$292.81	$2.09M
`M`	Option exercise derivative · Non-Qualified Stock Option (right to buy)	6,138	—	—

Filing: Form 4 (Insider Transaction) Insider: Haas Jason (Director) Shares: 7,138 Est. Value: $2.09M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-08-04

LGND insider Reardon Andrew (CLO & Secretary) sold 5,000 shares (~$1.44M)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`M`	Option exercise	5,000	$52.27	$261.4K
`S`	Open-market sale	105	$284.14	$29.8K
`S`	Open-market sale	33	$284.55	$9.4K
`S`	Open-market sale	157	$285.74	$44.9K
`S`	Open-market sale	1,032	$286.80	$296.0K
`S`	Open-market sale	1,214	$287.77	$349.4K
`S`	Open-market sale	356	$288.75	$102.8K
`S`	Open-market sale	503	$289.80	$145.8K
`S`	Open-market sale	200	$290.60	$58.1K
`S`	Open-market sale	991	$291.71	$289.1K
`S`	Open-market sale	409	$292.82	$119.8K
`M`	Option exercise derivative · Employee Stock Option (right to buy)	5,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Reardon Andrew (CLO & Secretary) Shares: 5,000 Est. Value: $1.44M

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-07-06

LGND insider Reardon Andrew (CLO & Secretary) sold 5,000 shares (~$1.57M)

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	132	$160.71	$21.2K
`M`	Option exercise	5,000	$52.27	$261.4K
`S`	Open-market sale	396	$308.99	$122.4K
`S`	Open-market sale	104	$310.20	$32.3K
`S`	Open-market sale	1,119	$311.72	$348.8K
`S`	Open-market sale	1,081	$312.28	$337.6K
`S`	Open-market sale	700	$313.46	$219.4K
`S`	Open-market sale	100	$314.58	$31.5K
`S`	Open-market sale	900	$315.78	$284.2K
`S`	Open-market sale	600	$317.15	$190.3K
`M`	Option exercise derivative · Employee Stock Option (right to buy)	5,000	—	—

Filing: Form 4 (Insider Transaction) Insider: Reardon Andrew (CLO & Secretary) Shares: 5,000 Est. Value: $1.57M

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-07-06

LGND insider Form 4 filed for equity award, exercise, or tax withholding

Espinoza Octavio (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	17	$160.71	$2.7K

Filing: Form 4 (Insider Transaction) Insider: Espinoza Octavio (Chief Financial Officer) Shares: 17

View on SEC EDGAR → Open Filing Document →

Form 4 Other reported transaction Tax / Compensation Filing 2026-07-06

LGND insider Form 4 filed for equity award, exercise, or tax withholding

Davis Todd C (Director, Chief Executive Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

The filing reports a transaction type that does not map to a routine purchase, sale, award or withholding.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`J`	Other transaction	132	$160.71	$21.2K

Filing: Form 4 (Insider Transaction) Insider: Davis Todd C (Director, Chief Executive Officer) Shares: 132

View on SEC EDGAR → Open Filing Document →

Proposed Insider Sales 4 · Form 144

A Form 144 is a notice of intent to sell restricted or control securities. It is not a record that anything was sold. Ligand Pharmaceuticals Incorporated has 4 such notices in this period.

The distinction matters because a Form 144 is frequently reported as though it were a completed insider sale. The filer may sell all of the shares covered, some of them, or none at all, and there is no obligation to update the notice either way. A sale that is actually executed by an officer or director shows up separately on a Form 4, which is the filing to check before treating a proposed sale as a real one.

Form 144 Proposed Insider Sale 2026-09-10

LGND Form 144 filed for proposed insider sale by MARTINE ZIMMERMANN (1,200 shares) ~$342.0K

MARTINE ZIMMERMANN filed a Form 144 with the SEC indicating intent to sell LGND (LIGAND PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: MARTINE ZIMMERMANN Shares: 1,200 Est. Value: $342.0K

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-09-03

LGND Form 144 filed for proposed insider sale by ANDREW REARDON (15,000 shares) ~$4.30M

ANDREW REARDON filed a Form 144 with the SEC indicating intent to sell LGND (LIGAND PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: ANDREW REARDON Shares: 15,000 Est. Value: $4.30M

View on SEC EDGAR → Open Filing Document →

Form 144 Large Proposed Insider Sale 2026-08-12

LGND Form 144 filed for proposed insider sale by OCTAVIO ESPINOZA (31,641 shares) ~$9.14M

OCTAVIO ESPINOZA filed a Form 144 with the SEC indicating intent to sell LGND (LIGAND PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4. The proposed dollar value is large enough to merit attention.

Filing: Form 144 (Proposed Sale Notice) Insider: OCTAVIO ESPINOZA Shares: 31,641 Est. Value: $9.14M

View on SEC EDGAR → Open Filing Document →

Form 144 Proposed Insider Sale 2026-08-12

LGND Form 144 filed for proposed insider sale by Jason Haas (7,138 shares) ~$2.09M

Jason Haas filed a Form 144 with the SEC indicating intent to sell LGND (LIGAND PHARMACEUTICALS INC) shares. Form 144 reflects a proposed sale, not a completed transaction. The actual execution, if any, would typically appear later in a Form 4.

Filing: Form 144 (Proposed Sale Notice) Insider: Jason Haas Shares: 7,138 Est. Value: $2.09M

View on SEC EDGAR → Open Filing Document →

Material Events 5 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 5 in this period for Ligand Pharmaceuticals Incorporated. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-09-24

LGND filed 8-K — material company event

LIGAND PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-09-22

LGND filed 8-K — material company event

LIGAND PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K/A Amended Material Company Update 2026-09-02

LGND filed amended 8-K — material company event

LIGAND PHARMACEUTICALS INC filed an amended 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K/A (Material Event Amendment)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-06

LGND filed 8-K — material company event

LIGAND PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-07-14

LGND filed 8-K — material company event

LIGAND PHARMACEUTICALS INC filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for Ligand Pharmaceuticals Incorporated.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-07

LGND filed Quarterly Report (10-Q)

LIGAND PHARMACEUTICALS INC filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify Ligand Pharmaceuticals Incorporated's filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on LGND. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — LGND SEC Filings

More Tools for LGND

LGND Full Stock Analysis LGND Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper LGND analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the LGND stock analysis page.

LGND Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer